You are here: Industry Insights > biosimilar

News List

As competition heats up, U.S. prices for Remicade and biosims slip: analyst fiercepharma
December 12, 2018
As Johnson & Johnson vies with biosimilars to its big-selling Remicade, prices across the category are gradually falling, an analyst says—and Pfizer's Inflectra has taken the biggest tumble.
Pharma caps U.K.’s branded-drug spend growth at 2% in exchange for faster drug launches fiercepharma
December 10, 2018
How much are pharma companies willing to pay in exchange for a faster trip to market in the U.K.? As it turns out, a cap of 2% on total branded-drug sales growth should do.
Boehringer Ingelheim axes biosimilars development outside US pharmaphorum
December 06, 2018
Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible.
Pfizer reaches a global agreement with AbbVie worldpharmanews
December 06, 2018
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.
Roche’s patent cliff just got steeper as FDA approves Celltrion’s Rituxan biosimilar Truxima fiercepharma
December 05, 2018
Roche’s trio of cancer blockbusters—Rituxan, Avastin and Herceptin—brought in $20 billion in sales last year, with one-fifth of that haul coming from lymphoma treatment Rituxan.
Oncolytics Biotech Appoints CMO contractpharma
November 30, 2018
Oncolytics Biotech announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as chief medical officer. Dr. Laeufle will oversee the clinical development plan for pelareo
FDA Approves First Biosimilar for Non-Hodgkin’s Lymphoma americanpharmaceuticalreview
November 29, 2018
The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive.....
EU OKs Mundipharma’s Neulasta biosimilar contractpharma
November 28, 2018
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
EC approves Mundipharma’s Pelmeg to treat febrile neutropenia pharmaceutical-technology
November 27, 2018
The Mundipharma network of independent associated companies has received European Commission (EC) approval for the use of Pelmeg (pegfilgrastim) for treatment of febrile neutropenia in adult cancer patients.
Sandoz to focus on more lucrative markets biospectrum
November 16, 2018
Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in the long term.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page